The European Medicines Agency (EMA) announced today that it hopes to have vaccines adapted to treat coronavirus variants, such as Omicron, which will be approved by September.
“Our priority is to ensure that customized vaccines are likely to be approved by September at the latest to be ready for new immunization campaigns in the EU in the autumn,” said Marco Cavaleri, head of biological threats to health and the EMA vaccine strategy.
“This will allow manufacturers to adapt their product lines accordingly.”
The mRNA vaccines developed by Pfizer-BioNTech and Moderna are the most advanced and clinical trials are ongoing.
It remains unclear whether the vaccines will target one or two variants in a single dose, Cavaleri added.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
